In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...
Read MoreMultiple Myeloma Posts on Medivizor
My Oncologist Doesn’t Believe Food Is Necessary
By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...
Read MoreEvaluating intensive CVD chemotherapy for patients with multiple myeloma
In a nutshell This study examined if intensive chemotherapy after initial chemotherapy made treatment more effective for patients with multiple myeloma (MM). The authors concluded that intensive chemotherapy increased survival without tumor growth or spread for these patients. Some background In MM, cancer cells become different...
Read MoreWhat factors can predict the success of stem cell transplantation?
In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...
Read MoreRecommendations for the treatment of multiple myeloma
In a nutshell This article provides recommendations for the treatment of multiple myeloma (MM). Some background MM is a type of blood cancer characterized by abnormal plasma cells. Plasma cells are a type of immune cell that antibodies to fight bacteria and viruses and stop infection and disease. In MM, abnormal plasma cells build up in the...
Read MoreLooking for patients with newly diagnosed multiple myeloma to test a combination therapy
In a nutshell This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois. The details Multiple myeloma (MM)...
Read MoreEvaluating lenalidomide-based regimens for elderly patients with multiple myeloma
In a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...
Read MoreEvaluating outcomes in patients with multiple myeloma after RVD therapy followed by stem cell transplant outside of clinical trials
In a nutshell This study assessed the safety and effectiveness of RVD (lenalidomide, bortezomib, dexamethasone) in patients with multiple myeloma before a stem cell transplant (SCT) in a real-life setting (outside of clinical trials). This study concluded that this treatment was safe and effective for these patients. Some background Multiple myeloma...
Read MoreCan levels of immune cells predict the outcomes of SCT for patients with multiple myeloma?
In a nutshell This study examined if the numbers of different immune cells before and after a stem cell transplant (SCT) predicted treatment outcomes for patients with multiple myeloma (MM). The authors concluded that the numbers of two types of immune cells and antibody levels were associated with a successful transplant. Some background MM...
Read MoreCould the addition of daratumumab to standard VTd treatment improve outcomes in multiple myeloma?
In a nutshell This study assessed whether the addition of daratumumab (Darzalex) to VTd (bortezomib, thalidomide, dexamethasone) therapy could improve response in patients with multiple myeloma (MM). The authors concluded that the addition of daratumumab improved the outcomes of these patients. Some background Autologous stem cell transplantation...
Read MoreEvaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...
Read MoreEvaluating a triplet regimen for patients with relapsed or refractory MM after lenalidomide therapy
In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...
Read More
